fibrin sealant

Drug Overview

Fibrin sealant is a highly specialized biological therapeutic agent used in the fields of hematology and surgery. Classified as a Topical Hemostatic, it is essentially a medical-grade “bio-glue.” Unlike traditional systemic hematology medications (like oral iron or IV blood factors), fibrin sealants are applied directly to a wound or surgical site. They are relied upon heavily in operating rooms to control bleeding, seal tissues, and promote localized healing when standard surgical techniques such as suturing, stapling, or electrocautery are ineffective or impractical.

• Generic Name: Fibrin sealant (Human fibrinogen and human thrombin)
• US Brand Names: Tisseel, Evicel, Artiss, Vistaseal
• Drug Class: Topical Hemostatic / Tissue Adhesive
• Route of Administration: Topical (Sprayed or dripped onto tissue)
• FDA Approval Status: Fully FDA-approved for use as an adjunct to hemostasis in specific surgical procedures.

What Is It and How Does It Work? (Mechanism of Action)

To understand how fibrin sealant works, it helps to look at the human body’s natural coagulation cascade. When a blood vessel is injured, the body stops the bleeding by using an enzyme called thrombin to convert a circulating protein called fibrinogen into long, sticky threads of fibrin. These threads weave together to form a solid, stable clot.

Fibrin sealant bypasses the entire complex cascade and skips straight to this final step. It is a two-component system, usually housed in a specialized dual-barrel syringe:

1. Component 1: Highly concentrated human fibrinogen.
2. Component 2: Highly concentrated human thrombin (often mixed with calcium chloride).

When the surgeon pushes the plunger, the two components are pushed through a mixing tip and applied directly to the bleeding tissue. The moment the thrombin meets the fibrinogen on the wound surface, it instantly converts the fibrinogen into a localized, stable fibrin clot. This reaction creates a physical, watertight seal in a matter of seconds to minutes, independently of the patient’s own coagulation system (making it highly effective even if the patient is on blood thinners or has a bleeding disorder like hemophilia). As the tissue heals over the following weeks, the body naturally absorbs and degrades the fibrin clot.

FDA-Approved Clinical Indications

Primary Indications

Fibrin sealants are indicated as an adjunct to hemostasis for mild to moderate bleeding in adult and pediatric patients undergoing surgery when control of bleeding by standard surgical techniques is ineffective or impractical.

Specific approved applications include:

• Cardiopulmonary Surgery: To seal bleeding heart tissue or graft sites.
• Hepatic and Splenic Surgery: To stop surface oozing on highly vascular organs like the liver or spleen.
• Colostomy / Intestinal Anastomosis: To create watertight seals over bowel sutures to prevent dangerous leaks.
• Skin Grafting: Brand names like Artiss are specifically formulated to adhere skin grafts to burn wounds.

Dosage and Administration Protocols

Because fibrin sealant is a surgical tool, its dosage is not measured in traditional milligrams per day, but rather by the surface area of the tissue that needs sealing.

Important Administration Rules:

• Topical Use ONLY: This product must never be injected directly into a blood vessel.
• Surface Preparation: The surgeon must blot or suction the target tissue as dry as possible immediately before application, as heavy active bleeding can wash the sealant away before it has time to set.
• Thin Layering: It is applied in a thin layer. Applying massive, thick clumps of sealant can actually impede the healing process.

Clinical Efficacy and Research Results

Clinical data consistently demonstrate that fibrin sealants significantly reduce time-to-hemostasis, lower the rate of post-operative blood transfusions, and reduce surgical drain output. In procedures like liver resections or complex cardiovascular bypass surgeries, the use of topical fibrin effectively seals microscopic capillary oozing that cannot be addressed with a needle and thread.

Furthermore, research emphasizes its utility in neurosurgery to seal the dura mater (the protective membrane around the brain and spinal cord) to successfully prevent cerebrospinal fluid (CSF) leaks, a common and dangerous post-operative complication.

Safety Profile and Side Effects

Strict Warnings

• Intravascular Injection Risk: If fibrin sealant is accidentally injected directly into a vein or artery, it will instantly cause a massive, fatal thromboembolism (blood clot) and cardiovascular collapse.
• Pathogen Transmission: Because the fibrinogen and thrombin are derived from pooled human plasma, there is a theoretical risk of transmitting infectious agents (such as viruses), despite rigorous donor screening and viral-inactivation manufacturing processes.

Common side effects (>5%)

Because this is applied topically during surgery, side effects are usually related to the surgical procedure itself, but can include:

• Post-operative fever
• Increased wound drainage or seroma (fluid buildup)
• Nausea (post-operative)

Serious adverse events

• Hypersensitivity / Anaphylaxis: Severe allergic reactions can occur. Some older or specific formulations may contain trace amounts of bovine (cow) proteins or synthetic antifibrinolytics (like aprotinin), which can trigger anaphylactic shock.
• Air/Gas Embolism: If the sealant is sprayed using a pressurized gas device, holding the spray tip too close to the tissue can accidentally force gas into the open blood vessels, causing a life-threatening air embolism.

Research Areas

Current hematological and bioengineering research is heavily focused on expanding the use of fibrin sealants beyond simple hemostasis. Scientists are utilizing the fibrin matrix as a localized “drug delivery system.” By mixing targeted antibiotics, chemotherapy agents, or stem cells into the fibrinogen before application, the resulting clot slowly releases the medication directly into the surgical bed over several weeks, fighting localized infection or promoting advanced tissue regeneration.

Disclaimer

The research discussed regarding the use of the fibrin matrix as a localized drug delivery system for targeted antibiotics, chemotherapy agents, or stem cells to promote advanced tissue regeneration is currently in the preclinical or early investigational phase and is not yet applicable to practical or professional clinical scenarios.

Patient Management and Practical Recommendations

(Note: Because this medication is administered exclusively by surgeons in an operating room, these protocols apply to the surgical and anesthesia teams.

• Preparation: The vials must be thawed from a frozen state or warmed to room temperature strictly according to the manufacturer’s guidelines to ensure the proteins do not denature.
• Equipment Verification: If using a pressurized spray applicator, the surgical team must strictly adhere to the manufacturer’s recommended distance (usually 10 to 15 cm from the tissue) and pressure limits to prevent fatal gas embolisms.
• Patient History: The anesthesia team must verify if the patient has a known severe allergy to human blood products, bovine proteins (if applicable to the specific brand), or prior severe reactions to aprotinin.

Legal Disclaimer

For informational purposes only; this document does not replace professional medical advice from a qualified healthcare provider. This content is not intended to be a substitute for professional medical diagnosis, treatment protocols, or clinical judgment. Always seek the advice of your physician or surgeon with any questions you may have regarding surgical procedures, bleeding risks, or medical interventions.